News and press releases

It is estimated that 10-15% of the world’s population are affected by chronic constipation¹ and that 6% struggle with faecal incontinence², both of which can cause physical discomfort and mental distress³. Although transanal irrigation treatment can help, the journey to treatment is often challenging with many patients left untreated. For some patients, symptoms are not considered severe enough, while others can feel intimidated by the existing treatments and product offerings, often leading to social isolation⁴.

“Transanal irrigation is a well-documented and effective treatment, but there are still many barriers that prevent people from getting the right care. With Peristeen Light we aim to help break down those barriers, enabling more people to access the treatment and improve their quality of life,” says Nicolai Buhl, Executive Vice President of Innovation.

Peristeen Light is designed to bring relief. It is a hand-held, low-volume transanal irrigation device that instils water into the rectum, thereby evacuating the stool from the lower bowel. Peristeen Light is developed based on 20 years of insights from Coloplast’s high-volume transanal irrigation device, Peristeen Plus. Peristeen Light is designed to be intuitive and easy to use, assembled in just two steps, and enables a smooth insertion into the rectum with a soft and flexible catheter.

The launch of Peristeen Light begins in February 2024 and the device is expected to be available in European markets over the next 12 months⁵.

Transanal irrigation treatment

Transanal irrigation is a procedure to manage bowel disorders by instilling water through a catheter to promote evacuation. The procedure helps regulate bowel movements and is often employed for symptoms like faecal incontinence and/or chronic constipation.

A growth driver in Bowel Care

Peristeen Light is a new transanal irrigation device within Coloplast’s Bowel Care segment. The addressable market for bowel care, comprised of transanal irrigation treatment, is estimated at around DKK 1 billion, growing at a high-single digit rate. Peristeen Light is expected to contribute to Coloplast’s growth trajectory for Bowel Care and help solidify the company’s global market leader position within transanal irrigation. 

Contacts

Peter Mønster

Sr. Media Relations Manager, Global Communications

+45 4911 2623

dkpete@coloplast.com

Aleksandra Dimovska

Sr. Director, Investor Relations

+45 4911 2458 

dkadim@coloplast.com

¹ Barberio B, Judge C, Savarino EV, et al. Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2021;6(8):638-48.

2 Sharma A, Yuan L, Marshall RJ, et al. Systematic review of the prevalence of faecal incontinence. The British journal of surgery. 2016;103(12):1589-97.

3 Coloplast, Market Study, The impact of bowel dysfunction of patients and HCPs, 2017, Data-on-file

4 Coloplast, Market Study, The impact of bowel dysfunction of patients and HCPs, 2017, Data-on-file

5 Note that Peristeen Light is a CE-marked medical device. Availability is dependent on the individual country's regulatory process. Not available in the US.

“We are now introducing new innovation to the US market, aiming to grow our presence within the foam dressings segment. We have a great product in our hands, and we have invested significantly in our sales organization to reach the full potential of this launch. I am really excited to get started,” says Kimberly Ditter, Vice President of Wound & Skin Care, North America.

Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually¹, while 2.5 million patients develop a pressure injury in acute care facilities each year². Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.

“Choosing the right dressing for wound treatment or pressure injury prevention should be simple and easy and give the patient a soft, secure and comfortable fit. Biatain Silicone Fit offers exactly that. It fits to the body, and it fits to the wound,” says Kimberly Ditter.

Fits to the body and fits to the wound

Biatain Silicone Fit with 3DFit Technology is designed for both pressure injury prevention and wound management. It stays securely in place during patient movement, fitting to body creases and allowing easy skin inspection as part of pressure injury prevention protocols³. It also matches the shape and depth of the wound bed up to 2 cm deep⁴, lowering the risk of infection and maceration for optimal wound healing conditions.

Biatain Silicone Fit comes in 12 different sizes and shapes to suit the facility’s needs. All sizes and shapes are developed and indicated for both pressure injury prevention and wound treatment to accommodate multiple purposes and a reduced number of SKUs.

Biatain Silicone Fit is available in the US as of January 2024.

Expanding Wound Care in the US

The global advanced wound dressings market is estimated at DKK 26-28 billion, with an annual estimated growth rate of 2-4%. Around 25-30% of the market is derived from the US, where products are typically used in the hospital setting.

1)     Sen CK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023 Dec;12(12):657-670. (LINK)

2)     Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. Int Wound J. 2019 Jun;16(3):634-640. (LINK)

3)     Coloplast data on file, 2022. Based on simulated use.

4)     Coloplast data on file 2023. Fit to the wound bed may vary across product design.

Contacts

Peter Mønster
Sr. Media Relations Manager, Global Communications
+45 4911 2623
dkpete@coloplast.com

Aleksandra Dimovska
Sr. Director, Investor Relations
+45 4911 2458
dkadim@coloplast.com